Safety and Efficacy of RN1201 Injection as First-Line Treatment for Newly Diagnosed Multiple Myeloma

NCT07652138 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

18

Enrollment

OTHER

Sponsor class

Conditions

Multiple Myloma
Newly Diagnosed Multiple Myeloma (NDMM)

Interventions

DRUG: BCMA/CD19-targeted allogeneic CAR-T

Sponsor

The First Affiliated Hospital of Soochow University